Dr. Chiu specializes in cancer research and biomedical signal transduction. As Molsentech’s Chief Biomedical Scientist, she focuses on the clinical translation of biomarkers—validating their diagnostic and prognostic value through clinical specimens. 

She has extensive experience leading government-funded projects and coordinating interdisciplinary collaborations across engineering and biomedical sciences, driving innovation in diagnostic technologies and their path to commercialization.

In developing biochip diagnostic platforms, Dr. Chiu bridges clinical needs with technological solutions, overseeing the design and execution of clinical trials. During the COVID-19 pandemic, she demonstrated end-to-end expertise from research and development to regulatory approval, co-developing a diagnostic product that successfully completed clinical validation and obtained tFDA EUA clearance — a contribution pivotal to advancing Molsentech’s technology and accelerating its